NeoStem Moves Forward on China Biopharma Acquisition
publication date: Oct 8, 2009
NeoStem, Inc. reported the SEC accepted its registration proposal to acquire China Biopharmaceutical Holdings in an all-stock transaction. China Biopharma’s only asset is a 51% interest in Suzhou Erye Pharmaceutical Co., a generic drug manufacturer that in 2008 produced $50 million in revenues and net income of $8 million. More details...
Stock Symbols: (NYSE Amex: NBS) (OTCBB: CHBP)
Sorry... this feature or article is only available to subscribers.